Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
LSLisata Therapeutics, Inc. logo

Lisata Therapeutics, Inc. (LSTA)

NASDAQ Capital Market · Currency in USD
$1.00 ▼ -0.01 (-0.91%)
At close: Oct 23, 4:00 PM ET. Market closed.
$1.00 ▲ +0.00 (+0.00%)
After hours: Oct 23, 4:10 PM ET

Summary

Previous Close
$1.01
Open
$0.99
Day's Range
$0.97 – $1.01
52 Week Range
$0.96 – $5.07
Volume
45,557
Avg. Volume
231,417
Market Cap
$8.97M
Beta (5Y Monthly)
0.80
PE Ratio (TTM)
--
EPS (TTM)
-$1.61
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
Oct 28, 2013
1y Target Est
--

Profile: Lisata Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
21
CEO
David J. Mazzo
Website
lisata.com

Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$1.13 · Revenue est. $659.00K
DateEst.Actual
Aug 6, 2026–-$0.32
May 14, 2026–-$0.50
Mar 12, 2026-$0.51-$0.74Miss
Nov 6, 2025-$0.54-$0.49Beat
Aug 7, 2025-$0.65-$0.54Beat
May 8, 2025-$0.53-$0.55Miss

Analyst view

Rating: Hold
Buy 0% · Hold 100% · Sell 0%

Get free alerts on LSTA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.